Iambic Files IND for AI Designed Brain Penetrant KIF18A Inhibitor IAM217
Iambic Therapeutics submitted an FDA IND on 5 October 2026 for IAM217, its second wholly owned AI discovered oncology candidate targeting KIF18A with reported brain penetration and strong preclinical intracranial tumor regression.
What changed
Iambic Therapeutics announced on 5 October 2026 that it submitted an Investigational New Drug application to the U.S. Food and Drug Administration for IAM217, a brain penetrant inhibitor of KIF18A for solid tumors with chromosomal instability, including triple negative breast cancer and ovarian cancer.
Iambic describes IAM217 as its second wholly owned AI discovered candidate to reach IND stage. The program used the company's structure prediction and property optimization stack, including tools branded Enchant, starting from roughly 100 initial hits identified across 24 high throughput experimentation plates. AI guided design reportedly drove potency to multiple 10 nanomolar class compounds while optimizing oral bioavailability, reducing cytochrome P450 mediated drug interaction risk, and engineering central nervous system penetrance.
In a preclinical brain metastasis model, Iambic reports IAM217 produced approximately 90% regression of established intracranial tumors. The company positions the allosteric binding mode as mechanistically selective over other kinesin family members and distinct from tubulin targeting cytotoxic liabilities.
Subject to FDA clearance, IAM217 would join IAM1363, a selective brain penetrant HER2 inhibitor already in Phase 1/1b, in Iambic's clinical pipeline. Iambic also anticipates submitting an IND for CDK2/4 dual inhibitor IAM C1 later in the fourth quarter of 2026.
Why it matters
Investors and pharma BD teams track whether AI discovery platforms produce IND ready assets with differentiated CNS exposure, not only faster hit finding. A second wholly owned AI originated IND within one portfolio strengthens the case that Iambic's workflow converts structural insights into developable oral drugs.
KIF18A has drawn industry interest as a synthetic lethal target in chromosomally unstable tumors. A brain penetrant molecule could matter for patients with CNS metastases where prior KIF18A efforts lacked adequate CNS exposure.
Who is affected
Oncology R&D leaders evaluating KIF18A should compare IAM217's reported CNS penetrance and selectivity rationale against competing programs before locking 2027 combination trial designs.
AI drug discovery vendors face higher proof bars: partners will ask for IND counts, not only cycle time reductions on hit generation.
Clinical investors should model Iambic's Phase 1/2 start timing contingent on FDA clearance and watch overlap with IAM1363 CNS active HER2 work.
What to do next
If your team tracks synthetic lethal oncology targets, request Iambic's public conference data on IAM217 PK and brain penetration models and map patient selection biomarkers for chromosomal instability before committing co development discussions.
What to watch
FDA clearance letter timing and whether Iambic opens trial sites in CNS metastasis cohorts in the first protocol amendment. A delay beyond first quarter 2027 or exclusion of brain metastasis arms would weaken the differentiated CNS thesis.
Sources
- Primary. Iambic Therapeutics, Iambic submits IND for potentially brain penetrant KIF18A inhibitor IAM217 (5 October 2026). IND submission date, AI discovery workflow, 90% intracranial regression claim, and pipeline context.
- Secondary. BioSpace coverage of Iambic IAM217 IND (5 October 2026). Independent restatement of target indication and second AI discovered asset framing.